Osiris Therapeutics
-
Financial
Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing…
Read More » -
Financial
Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.
LONDON, March 12, 2019 /PRNewswire/ — Smith & Nephew plc (LSE: SN,NYSE: SNN), the global medical technology business, announces that it has agreed to…
Read More » -
Biologics
Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
COLUMBIA, Md., Nov. 26, 2018 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing…
Read More » -
Financial
Osiris Therapeutics, Inc Reports Third Quarter 2018 Results
COLUMBIA, Md., Nov. 07, 2018 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing…
Read More » -
Biologics
Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada
COLUMBIA, Md., Oct. 30, 2018 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing…
Read More » -
Biologics
Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018
COLUMBIA, Md., Sept. 17, 2018 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing…
Read More » -
Financial
Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018
COLUMBIA, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing…
Read More » -
Biologics
Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
COLUMBIA, Md., Feb. 06, 2018 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors,…
Read More » -
Financial
Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
COLUMBIA, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (OTC Pink:OSIR) (the “Company”), a leading regenerative medicine company focused on developing and…
Read More » -
Biologics
Osiris Appoints Linda Palczuk to serve as its President & CEO
COLUMBIA, Md., June 26, 2017 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board…
Read More » -
Biologics
Osiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
COLUMBIA, Md., March 30, 2017 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on…
Read More » -
Financial
Zacks Investment Research Lowers Osiris Therapeutics, Inc. (OSIR) to Sell
By Jeff Rose Zacks Investment Research lowered shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) from a hold rating to a sell…
Read More » -
Financial
Osiris Therapeutics, Inc. (OSIR) Downgraded by Zacks Investment Research to Sell
By Mark Watkins Osiris Therapeutics, Inc. (NASDAQ:OSIR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a…
Read More » -
Financial
Osiris Therapeutics Announces Third Quarter 2015 Financial Results
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions…
Read More » -
Financial
Zacks Upgrades Osiris Therapeutics to Hold (OSIR)
By Mark Watkins Osiris Therapeutics (NASDAQ:OSIR) was upgraded by Zacks from a “sell” rating to a “hold” rating in a report released on Tuesday, Market Beat.com reports.…
Read More »